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NIM811Three cyclophilin inhibitors (DEBIO-025, SCY635, and NIM811) are currently in clinical trials for hepatitis C
therapy. The mechanism of action of these, however, is not completely understood. There are at least 16
cyclophilins expressed in human cells which are involved in a diverse set of cellular processes. Large-scale
siRNA experiments, chemoproteomic assays with cyclophilin binding compounds, and mRNA proﬁling of
HCV replicon containing cells were used to identify the cyclophilins that are instrumental to HCV replication.
The previously reported cyclophilin A was conﬁrmed and additional cyclophilin containing pathways were
identiﬁed. Together, the experiments provide strong evidence that NIM811 reduces viral replication by
inhibition of multiple cyclophilins and pathways with protein trafﬁcking as the most strongly and
persistently affected pathway.
© 2009 Elsevier Inc. All rights reserved.Introduction
More than 170 million people worldwide are chronically infected
with the hepatitis C virus (HCV), a major cause of chronic hepatitis,
cirrhosis, and hepatocellular carcinoma (World Health Organization,
1999). Chronic HCV infection has also become the most common
indication for liver transplantation in the US. The current therapy
includes pegylated interferon and ribavirin (Feld and Hoofnagle,
2005). Unfortunately, this treatment covers only about 50% of the
prevalent genotypes and is poorly tolerated (reviewed in (Feld and
Hoofnagle, 2005)). Thus, new drugs with broad genotype activity and
low toxicity are in high demand.
HCV is a small enveloped virus that belongs to the Hepacivirus
genus of the Flaviviridae family. Its RNA genome encodes a single
polyprotein precursor of about 3,000 amino acid residues, which is
cleaved by cellular and viral proteases to yield at least 10 viral
proteins (reviewed in (Branch et al., 2005)). These proteins are
necessary for the replication of viral RNA and for the assembly of
viral particles. In addition, the virus depends on numerous hostublished while the manuscript
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ll rights reserved.proteins to complete its life cycle (examples in (He et al., 2007),
(Randall et al., 2007), and (Polyak, 2003)). Targeting host proteins
represent a successful anti-HCV strategy as proven by the viral load
reduction in the clinical trial of the cyclophilin inhibitor DEBIO-025
(Flisiak et al., 2008).
Cyclosporin A (CsA) has been shown to have anti-HCV activity
in combination with interferon in a clinical trial (Inoue et al., 2003).
Recently, a 3.5 log reduction of viral load has been demonstrated
with the CsA analog DEBIO-025 (Flisiak et al., 2008). The
compounds are inhibitors of cyclophilins, proteins of the peptidyl-
prolyl cis-trans isomerase family. In humans, nineteen cyclophilin
isoforms with different cellular and tissue distribution have been
described (Galat, 2004). They are all potential targets of CsA and its
analogs such as DEBIO-025 and NIM811, but only a few cyclophilins
have been studied in more detail. The knowledge on the cellular
functions of the various cyclophilin isoforms and how they
modulate HCV replication is currently limited.
Several laboratories investigated the roles of individual cyclo-
philins in HCV replication and their results have been inconsistent.
Employing the replicon in vitro system, cyclophilin B but not A was
shown to be involved in viral RNA replication (Watashi et al.,
2005). Nakagawa et al (Nakagawa et al., 2005) showed that siRNA-
mediated reduction of mRNA levels of cyclophilin A, B, or C
decreases replicase activity while three laboratories reported
cyclophilin A as the critical host factor for HCV (Yang et al.,
2008; Chatterji et al., 2009; Hanoulle et al., 2009). We analyzed the
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RNAi, pharmacological tool compounds, and quantitative chemical
proteomics to demonstrate that the replicon depends on the
activity of several cyclophilins. We performed siRNA screens and
compound competition experiments in HCV replicon cells to detect
proteins in pathways where cyclophilins were involved. In addition,
we employed the cyclophilin-binding compounds, NIM811 and CsA,
in RNA proﬁling studies to identify pathways affected in naïve vs.
replicon-containing cells. Together, these approaches demonstrate
that HCV replication relies on several cellular pathways linked to
cyclophilins A, H, 40, and E.
Results
Cyclophilin binding correlates with activity in replicon assay
We have demonstrated previously that the activity of cyclosporine
derivatives in an HCV replicon assay correlates with the binding to
cyclophilin A (Ma et al., 2006).We extended the cyclophilins analyzed
to include Cyclophilin B, C, F, 40 and H (Table 1) and used Surface
plasmon resonance (SPR) to study the interaction of CsA and NIM811
with cyclophilins (Table 2). SPR has the advantage to operate with
unmodiﬁed compounds and provides information on kinetic para-
meters. With bothmethods we obtained similar results: NIM811 has a
higher afﬁnity for all cyclophilins than CsA and the binding afﬁnity
ranks in the order Bb A/Fb Cb Hb 40. The higher afﬁnity of NIM811
vs. CsA is due to a larger kon and smaller koff for all cyclophilins
resulting in a lower KD.
We also tested Sanglifehrin A derivatives, cyclophilin-binding
macrocycles of different chemical structure (Sedrani et al., 2003) and
investigated their binding activities to cyclophilins and their HCV
inhibitory activities. Several derivatives bind to cyclophilins A, B, C
and F and inhibit HCV replication (Table 1). The sanglifehrin A analog,
compound 7 like the cyclosporin analog PSC833 binds much weaker
to cyclophilins and exhibits low activity in the HCV replicon assay.
Only cyclophilin-binding cyclosporin or sanglifehrin analogs reduced
viral replication suggesting that one or more of these cyclophilins play
a role in HCV replicon maintenance.
siRNA-mediated down-regulation of mRNA levels of cyclophilins inhibits
viral replication
The binding afﬁnities of the compounds to the different
cyclophilins varied up to ten-fold (Tables 1 and 2). Since the
cellular cyclophilin levels vary by the same factor (GeneCard®,
XenneX, Inc.), it was not possible to identify a particular
cyclophilin as the crucial mediator for replication of viral RNA by
correlating binding afﬁnities and effect on replication. To directly
investigate the roles of the different cyclophilins, we down-
regulated the mRNA levels of individual cyclophilins using siRNAs
and measured the effect on viral RNA replication by monitoring
activity of the reporter gene ﬁreﬂy luciferase or by quantifying viral
RNA levels by QRT-PCR. Fig. 1a shows that each siRNA used
speciﬁcally reduces its target mRNA when compared with a non-
targeting siRNA, with small effects on expression of the other
cyclophilins. Cyclophilin E siRNA results also in a slight (b25%)
decrease of cyclophilins A, B, and C. Down-regulation by siRNA of
some cyclophilins caused an upregulation of others, e.g. cyclophilin
A depletion resulted in a higher expression of cyclophilins B, C, and
40. In Huh-Luc/neo-ET cells, siRNA mediated knockdown of
cyclophilin A has the largest impact on replication, with less than
20% of replicon activity remaining after 96 h (Fig. 2b). Cyclophilin
H, 40, and E knockdown had a less pronounced but statistically
signiﬁcant effect (p=0.04, 0.03 and 0.02 at 96 h, respectively,
compared with non-targeting siRNA by students t-test), decreasing
replicon activity by 30–50%, whereas cyclophilins B, C, and F arenot important for this speciﬁc replicon model. Cyclophilin G
depletion even stimulated replication.
Identiﬁcation of proteins interacting with NIM811 and CsA using
chemical proteomics
To identify cellular and viral proteins from Clone A cells interacting
speciﬁcally with NIM811 and CsA but not with the inactive compound
PSC833, we performed an afﬁnity puriﬁcation experiment using an
active analog of NIM811 (NIM811-NH2) linked to Sepharose beads
as a matrix. Clone A cell lysate was preincubated for 30 min with
competing compounds cyclosporin A (CsA) and NIM811, the non-
competing cyclosporin analog PSC833, or DMSO as control. NIM811-
NH2 beads were then added for 30 min and proteins bound to the
matrix were puriﬁed. Protein targets of active cyclosporin analogs are
expected to bind (directly or via a bridging protein that could be
cyclophilin) free CsA and/or NIM811 and be poorly retrieved by the
NIM811-NH2 matrix in presence of these drugs, but be fully
precipitated when only DMSO or the inactive compound PSC833
was added. All four puriﬁcations (in presence or absence of competing
compounds) were performed in parallel and eluted proteins were
separated by SDS-PAGE. Samples were processed, labeled with iTRAQ
and analyzed by LC-MS/MS for protein identiﬁcation and quantiﬁca-
tion as described in Material and methods. Supplementary table S2
lists all 636 proteins that were identiﬁed by MS. Out of these, 327 met
the acceptance criterion for robust quantiﬁcation of four or more
spectra matching to unique peptides. As expected, few proteins were
strongly competed by 5 μM of PSC833. In contrast, a large number of
proteins were strongly competed in presence of 5 μM NIM811 or CsA.
Table 3 lists 51 proteins that were competed at least 50% with both
NIM811 and CsA but less than 25% with PSC833. Not surprisingly,
amongst themost strongly competed proteins by CsA and NIM811 but
not PSC833 are several cyclophilins. Out of nine quantiﬁed cyclophi-
lins, sevenwere competedmore than 85% in presence of both NIM811
and CsA (PPIH, PPIA, PPIL1, PPIE, PPIF, PPIB, PPIC). Other highly
competed proteins include splicing factors (SNRPs, PRPFs, LSMs) and
extracellular matrix proteins (Laminins, Syndecans, Leprecans). HCV
non-structural protein NS4B was precipitated by the matrix but the
identiﬁcation was not strong enough to allow for robust quantiﬁca-
tion. Competed proteins can be grouped according to their subcellular
localization and function (Fig. 2). They could possibly associate with
the cyclophilins present in the same compartment. Two large clusters
represent proteins involved in mRNA splicing and ER localized
proteins. The latter group includes extracellular matrix proteins en
route to the plasma membrane and their secretion.
siRNA-mediated down-regulation of mRNAs of the proteins pulled-down
by NIM811 and CsA reveals impact on viral replication
The identiﬁed hits from the pull-down experiments were tested
for their requirement in viral RNA replication. Multiple siRNAs
targeting each the mRNA of the proteins listed in Table 3 were
transfected into Huh-Luc/neo-ET cells and the effect of the
reduction of the mRNA levels was analyzed by measuring luciferase
reporter gene activity. In order to reduce the siRNA number, only
one or two of several hits were included in this validation process
when these hits are known to form complexes such as the
spliceosomal complex. Table 4 shows the siRNAs which reduce
viral replication ≥40% as compared to ‘no siRNA’ control. Several
siRNAs targeting LEPREL1, LEPRE1, PPWD1, HSPA8, RAB43, AGRN,
SART3 reduced viral replication. One or two siRNAs were identiﬁed
to reduce viral replication for the spliceosomal proteins SNRPD1
and 3, SNRPB, SNRPN, NHP2L1, XAB2, SNW1. Although none of the
siRNAs targeting LSM3 and 4 had an effect on replicon activity,
siRNAs targeting components of the same complex, LSM 2 and 6,
were able to reduce viral replication.
Table 1
Correlation of anti-HCV and cyclophilin-binding activities of compounds.
Replicon Cyp A Cyp B Cyp C Cyp F Cyp 40 Cyp HCompound
IC50 [μM] KD [nM]
CsA derivatives
CsA 0.45 26 14 190 30 360 250
PSC833 12 2600 3400 N3500 2100 N3300 N3300
NIM811 0.10 13 3.4 32 6.7 130 82
NIM811-NH-Boc 0.15 23 6.9 67 13 220 92
Sanglifehrins
Compound 3 2.5 19.7 10.3 31.9 50.0 496.7 78.7
Compound 4 4.11 223.0 79.3 425.5 800.0 2516.6 160.7
Compound 5 5.6 19.7 6.9 35.5 60.0 993.3 88.5
Sanglifehrin A 5.9 13.8 21.4 9.2
Compound 6 200 N3278.7 N3448.3 N3546.1 N3333.3 N3311.3 N3278.7
Compound 7 0.13 14.1 9.3 13.5 21.7 185.4 28.5
Compound 4 was previously published with an IC50 of 30 nM for CypA (Sedrani, Kallen et al., 2003).
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trafﬁcking as important for viral replication
Next we screened two siRNA libraries in Huh-Luc/neo-ET cells
to identify cellular proteins and pathways necessary for replication.
Two libraries were tested: a kinome siRNA library and a library
containing siRNAs targeting ∼3000 druggable genes. The hits werefurther validated with four distinct siRNAs targeting each gene and
only those where two or more siRNAs reduced viral replication
were considered as hits. Fig. 3 summarizes the identiﬁed proteins
of both screens clustered into pathways. The detection of pathways
known to affect HCV replication such as pyrimidine-de-novo
synthesis and cholesterol biosynthesis validated the screen. Con-
sistent with the data obtained by our other approaches, the largest
Table 2
Kinetics and binding afﬁnity of CsA and NIM811 to cyclophilins.
Cyclophilin A Cyclophilin B Cyclophilin C Cyclophilin H Cyclophilin 40
NIM811 CsA NIM811 CsA NIM811 CsA NIM811 CsA NIM811 CsA
kon (M−1 s−1) 8×105 4×105 7×105 4×105 6×105 2×105 2×105 1×105 5×105 2×105
koff (M−1 s−1) 0.005 0.010 0.002 0.003 0.006 0.010 0.008 0.020 0.030 0.080
t1/2 (min) 2.30 1.18 7.45 3.73 1.81 1.00 1.46 0.67 0.37 0.14
KD (nM) kinetic 6.14 24.7 2.23 7.96 10.8 52.6 32.5 142 58.0 441
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pathways.
Comparison of mRNA proﬁles of naïve versus Clone A cells with
and without NIM811 or CsA treatment
We performed twomRNA proﬁling experiments with NIM811 and
CsA in naïve Huh7 cells and Clone A replicon cells (Tables 5, 6, com-
plete data set is available http://www.ncbi.nlm.nih.gov/geo). The
mRNA changes observed after compound treatment were both con-Fig. 1. siRNA-mediated reduction of mRNA levels of four cyclophilins causes decrease in H
transfected into Huh-Luc/neo-ET cells and the mRNA levels of their targets and other cyclo
non-targeting siRNAwas set to a value of 1, not shown). (b) Replication was measured by luc
siRNA is shown compared with a non-targeting siRNA. CypA, cyp40, cypE and cypH siRNAs re
by Student's t-test compared with non-targeting siRNA).centration and time dependent with a larger effect at higher concen-
tration and shorter treatment time (data not shown). The affected
mRNAswere overlapping in each treatment: the same pathways were
either down- or up-regulated independent from drug concentration
or treatment time. NIM811 and CsA caused similar changes at the
level of gene expression but NIM811 was more potent at comparable
concentration and treatment time.
The Gene Set Enrichment Analysis (GSEA) detects small and
coordinated changes of a functionally related group of genes from
expression analysis data (Szustakowski et al., 2006). GSEA takes inCV replication. (a) 25 nM siRNA targeting cyclophilins or a non-targeting siRNA were
philins quantiﬁed relative to a non-targeting siRNA after 72 h (gene expression for the
iferase activity at 72 and 96 h after siRNA transfection. Relative replicon activity for each
sult in a statistically signiﬁcant decrease in viral replication at both time points (pb0.05
Fig. 2. Distribution of NIM811 and CsA binding proteins to cellular compartments and pathways. Proteins interacting with NIM811 and CsA but not with the control substance
PSC833 (see Table 3) as determined by in-lysate competition are clustered to their location and possible interaction with cyclophilins. Reduction of mRNA levels of the bold labeled
proteins by siRNA reduced viral replication at least 40% (Table 4). siRNA of the proteins in brackets and bold font have not been tested with siRNA but siRNAs targeting other
components of the complex these proteins are integrated in were identiﬁed. Proteins in brackets did not score in the siRNA test but they are known components of a protein complex
for which other members showed inﬂuence on HCV replication.
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strength of regulation and expresses both as a signiﬁcance value (p-
value). Since genes can be part of several different pathways, we
performed a clustering of pathways by combining pathways which
contain the same regulated genes into one cluster. Table 5
summarizes the pathways most signiﬁcantly regulated by the
replicon grouped into pathway clusters. In addition, the table
contains information on how these pathways were regulated in the
presence of NIM811 and how they are affected by NIM811 in naïve
cells. In replicon containing cells, genes involved in protein
biosynthesis were down-regulated while genes in immunity and
ATP generating pathways were up-regulated. For most pathways,
treatment of replicon-containing cells with NIM811 induced
changes that are inversely correlated to the changes induced by
the replicon itself. This inverse relationship is most likely due to
inhibition of viral replication since NIM811 has no effect in naïve
Huh7 cells (Table 5, column 5). One exception is intracellular
protein trafﬁcking, which is strongly up-regulated in naïve cells by
NIM811 treatment (Table 6) as well as by the replicon. Additionally,
cadherin signaling and developmental processes were down-
regulated by NIM811 and by the replicon (Tables 5 and 6). Table
6 demonstrates that protein trafﬁcking was the most signiﬁcantly
up-regulated pathway by NIM811 treatment. Processes that depend
on the transport of proteins to the cell surface and mediate cell–cell
contact, cell adhesion and communication, were down-regulated.
Discussion
The anti-HCV activity of cyclosporin A and NIM811 has been
attributed to their binding to cyclophilin B (Watashi et al., 2005; Liu et
al., 2009) and recently to cyclophilin A (Yang et al., 2008; Fernandes etal., 2007; Chatterji et al., 2009; Hanoulle et al., 2009). Chemically
unrelated cyclophilin inhibitors, the sanglifehrins, exhibit the same
effect supporting the hypothesis that (a) cyclophilin(s) is/are
necessary for HCV replication. Nineteen open reading frames encod-
ing cyclophilins have been identiﬁed in the human genome. All
contain a conserved catalytic domain that is responsible for the cis/
trans isomerisation of peptidyl-prolyl amino acid bonds (Galat, 2004).
Cyclophilins are distinct in their tissue expression and subcellular
localization. We sought to identify host factors or pathways that
regulate viral replication using small interfering RNA-mediated
down-regulation of mRNAs, compound pull-down, and mRNA
proﬁling. Together, the results of these approaches lead to the
conclusion that several cyclophilins are necessary for HCV replication.
A similar observation was reported recently (K.-I. Abe et al., abstract
387, presented at the 15th International Symposium on Hepatitis C
Virus and Related Viruses, San Antonio, TX, 2008). Our mRNA
depletion experiments showed that cyclophilin A, H, and to a lesser
extent 40, and E participate in pathways required for efﬁcient viral
replication in Huh-Luc/neo-ET cells.
The results of the siRNA experiments are supported by the pull-
down of proteins in pathways containing different cyclophilins. The
spliceosome contains several cyclophilins, such as cyclophilin H, E, L1,
L3 and PPWD1. Therefore it was not surprising that a large number of
proteins (∼37% of all hits) interacting with these cyclophilins were
identiﬁed in the compound pull-down experiment even though the
afﬁnity of the compounds to CypH is weaker than to other cyclophilins
(Table 1). The observation that a decrease of spliceosomal proteins by
siRNA treatment diminished viral replication without being toxic to
the cell was quite unexpected since the viral RNA does not need
splicing. The largest group of proteins (∼43%) identiﬁed in the pull-
down experiment is involved in protein trafﬁcking processes and
Table 3
Proteins showing signiﬁcantly stronger competition by NIM811 and CsA (N50%) over
PSC833 (b25%).
Representative Gene Competition relative
to DMSO control
mRNA
regulated
in replicon
containing
vs. naive
Huh7 cells
mRNA
regulated
in NIM
treated vs.
untreated
Huh7 cells
CsA NIM811 PSC833
IPI00479925.1 AGRN 89.4 90.7 22.1
IPI00297572.4 AQR 81.7 84.9 7.3
IPI00420014.2 ASCC3L1 57.2 62.1 −29.5
IPI00440493.2 ATP5A1 69.8 53.3 −8.7
IPI00043565.3 CCDC16 79.3 76.0 −89.2 1.7
IPI00437593.1 COL18A1 79.1 78.3 9.8 −1.7
IPI00220959.7 CRTAP 88.7 77.1 −144.2 1.7
IPI00177366.2 DHX15 70.8 64.7 −45.2
IPI00001755.1 GPC6 85.5 75.1 −15.5
IPI00031522.2 HADHA 87.3 86.6 −7.9
IPI00003865.1 HSPA8 73.4 55.9 −86.9
IPI00024284.4 HSPG2 81.5 76.6 11.8
IPI00641693.2 LAMA5 90.6 88.8 11.9
IPI00013976.1 LAMB1 88.4 84.8 −5.4
IPI00004503.4 LAMP1 75.4 64.2 −9.5 1.7
IPI00045839.2 LEPRE1 96.9 92.8 −1.8
IPI00217055.1 LEPREL1 89.9 83.4 −7.6
IPI00032460.3 LSM2 80.8 90.2 3.8
IPI00219229.2 LSM3 78.9 85.2 5.7
IPI00001146.1 LSM6 77.0 78.5 −4.9
IPI00007163.1 LSM7 74.5 83.3 −6.7
IPI00219871.4 LSM8 82.2 86.4 19.5
IPI00026167.2 NHP2L1 84.1 88.3 14.0
IPI00026944.2 NID1 73.9 68.6 −10.3 −1.9
IPI00480133.1 PPIA 95.6 96.2 −7.2
IPI00024129.1 PPIC 92.3 88.7 10.9
IPI00003927.4 PPID 66.1 77.9 14.1 −1.5
IPI00514173.1 PPIE 93.3 91.2 −0.6
IPI00026519.1 PPIF 95.6 90.5 −18.4
IPI00007346.1 PPIH 92.5 97.4 −38.5
IPI00007019.1 PPIL1 89.3 93.9 −11.3
IPI00149650.3 PPWD1 66.4 84.1 9.2
IPI00021146.1 PRPF18 67.3 83.9 −0.1 1.6 −2
IPI00005861.1 PRPF3 78.8 85.2 3.5
IPI00292000.6 PRPF31 78.3 77.4 −50.9
IPI00150269.1 PRPF4 77.4 84.0 −14.5 1.7
IPI00007928.4 PRPF8 66.9 66.1 11.1
IPI00556031.2 RAB43 84.5 82.2 −23.4
IPI00304935.4 SAAL1 80.6 73.0 −17.7
IPI00006025.1 SART3 70.7 80.4 5.9
IPI00002441.1 SDC1 93.2 91.6 17.5 −1.7
IPI00300407.3 SDC2 94.4 93.7 10.4 1.5
IPI00329512.3 SNRPB 69.7 75.9 −4.8
IPI00017963.1 SNRPD2 71.8 78.9 18.3
IPI00029266.1 SNRPE 77.7 82.8 0.0 −2.5
IPI00220528.6 SNRPF 66.4 64.0 −10.3
IPI00016572.1 SNRPG 74.0 80.4 −21.1
IPI00013830.1 SNW1 84.0 81.9 −10.3 1.5
IPI00290566.1 TCP1 76.4 57.8 −62.4
IPI00163084.3 XAB2 90.7 91.0 −12.3 −2.2
The mRNA levels are presented as fold-shifts and 1.5 was used as the cut-off value.
Table 4
NIM811/CsA interacting proteins affecting viral replication.
Accession no. Average RLU Number of siRNAs GeneData ID
NM_198576 2912 5 AGRN
NM_052857 2860 1 CCDC16
NM_006597 2810 6 HSPA8
NM_005561 2697 6 LAMP1
NM_022356 2857 6 LEPRE1
NM_018192 2890 4 LEPREL1
NM_021177 3226 3 LSM2
NM_007080 3020 1 LSM6
NM_001003796 2992 5 NHP2L1
NM_015342 3104 5 PPWD1
NM_004697 3240 2 PRPF4
NM_020701 3240 4 RAB43
NM_138421 3147 3 SAAL1
NM_014706 3115 4 SART3
NM_198216 3220 1 SNRPB
NM_006938 2720 1 SNRPD1
NM_004175 3273 3 SNRPD3
NM_003095 2980 1 SNRPN
NM_012245 2980 1 SNW1
NM_020196 2960 1 XAB2
888 (n=18) pGL2
5658 (n=22) no siRNA
Multiple siRNAs per gene for the proteins identiﬁed as NIM811/CsA interacting in pull-
down competition assays were tested at 25 μM concentration in cells containing the
Huh-Luc/neo-ET replicon. The luciferase reporter signal was measured in duplicate
plates. Proteins for which the average luciferase signal was decreased ≥40% compared
to the ‘no siRNA’ signal are listed in the table.
Fig. 3. Host proteins identiﬁed in siRNA screens to affect HCV replication. The kinome
and the 5000 druggable gene siRNA libraries were transfected into Huh7 cells
containing the Huh-Luc/neo-ET replicon and their effect was measured by luciferase
reporter gene activity. Hits from the two screens were further tested by a secondary
siRNA knock-down experiment. Proteins identiﬁed in both experiments were clustered
into cellular pathways.
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proteins NS3, NS4B, NS5A and NS5B were precipitated by the matrix
but none have been signiﬁcantly competed by the addition of either
NIM811 or CsA, indicating that the possible interaction between viral
proteins and cyclophilins is weaker than the interaction of cyclophi-
lins with known cellular interacting proteins. Alternatively, the
interaction may be of a transient nature, and conformational changes
upon binding may occur which prevent a stable interaction. The NS5A
and NS5B proteins have recently been shown to be substrates of
cyclophilins A and B (Hanoulle et al., 2009). The same pathway,
protein trafﬁcking, has been identiﬁed to be affected by the viral
replicon as well as by NIM811 with a gene expression proﬁling
approach.In the following section we will link the evidence from our
experiments for the function of various cyclophilins with their roles
described in the scientiﬁc literature. This analysis suggests that several
cyclophilin-containing pathways are necessary for viral replication.
Table 5
Modulation of pathways by HCV replicon and/or NIM811 treatment.
Pathway cluster Pathway name Replicon vs.
Huh-7 cells
NIM811 treated
vs. untreated
Replicon cells
NIM811 treated
vs. untreated
Huh-7 cells
Downregulated
Protein biosynthesis Ribosome −7.7 1.0 −0.1
Protein biosynthesis −4.5 0.4 2.5
Aminoacyl-tRNA biosynthesis −6.6 0.4 0.4
Map00970_aminoacyl_tRNA_biosynthesis_mootha −5.9 0.2 0.2
Amino acid activation −5.8 0.4 0.4
Other Developmental processes
Cadherin signaling pathway −3.9 −0.7 −8.5
Oncogene −3.6 0.8 −0.7
Glycosylphosphatidylinositol(gpi)-anchor biosynthesis −3.6 0.7 −0.7
Ectoderm development −3.1 −0.4 −3.8
Other apoptosis −3.0 1.6 −0.3
Upregulated
Other Intracellular protein trafﬁc 5.0 5.8 61.0
Sulfur metabolism 5.2 −1.2 1.8
Mitosis 5.7 −0.7 0.8
Cytokinesis 5.7 −0.8 −0.2
Map03070_typt_III_secretion_system_mootha 5.7 −1.9 1.2
Signaling signaling:homosapiens:disease:rheumatoid arthritis:osm
signaling pathway
5.3 −1.1 −0.2
signaling:homo sapiens:disease:acquired immuno deﬁciency
syndrome:tat signaling pathway
5.8 −1.3 1.9
signaling:homosapiens:physiology:cell adhesion:csf signaling pathway 7.8 −1.5 −0.3
Energy generation Glycolysis/gluconeogenesis 5.3 −7.5 0.5
Map00193_atp_synthesis_mootha_human 5.7 −1.9 1.2
Map00195_photosynthesis_mootha_human 6.0 −2.0 1.1
Mitochondria_mootha_human 8.0 −15.3 0.1
Atp synthesis 8.4 −7.5 0.4
Oxidative phosphorylation 9.0 −21.1 −0.1
Human_mitodb_6_2002_mootha_human 9.4 −18.3 −0.2
Carbohydrate metabolism 11.4 −6.2 1.4
Immunity t-cell mediated immunity 5.5 −4.5 −1.9
Mhc I-mediated immunity 11.6 −4.9 −1.0
The numbers represent the negative exponent of the p value reported in GSEA. The p value expresses the probability that a gene set is enriched by chance. The “−” preceding the
number indicates the directionality of regulation; e.g. if it is negative it indicates an overall down-regulation, if it is missing it indicates an up-regulation. The pathways were sorted to
identify the strongest regulation in “replicon vs. Huh-7 cells.”
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Cyclophilin A is reported to be a cytosolic soluble enzyme and its
most commonly known function is the modulation of T-cell mediated
immune response in a complex with cyclosporin A. The cyclosporin-
cyclophilin complex binds to calcineurin and inhibits its phosphatase
activity which prevents themigration of NF-κB into the nucleuswhere
it activates gene transcription of IL-2, IFN and other chemokines
typical for the T-cell immune response (Clipstone and Crabtree,
1992). This mechanism is exploited when CsA is used to prevent
rejection of transplants by inﬂammatory responses (Borel, 2002).
Besides its role as cis/trans prolyl isomerase cyclophilin A has also
been implicated in cholesterol transport. It has been detected in
complex with FKBP56, cyclophilin 40 and caveolin transporting
cholesterol in a CsA sensitive manner to caveolae (Uittenbogaard et
al., 1998). Another mechanism of cytosolic cholesterol transport
between different membranes is mediated by lipid droplets which
also contain caveolin and, as recently explored to greater detail, HCV
proteins (Boulant et al., 2007;Miyanari et al., 2007). Overexpression of
Rab18 causes disappearance of adipophilin from lipid droplets and
subsequently to the association of the droplets with the ER next to the
translocon, the site where the HCV core protein enters the membrane
and the droplets bud (Ozeki et al., 2005). Lipid rafts are yet another
vehicle for protein and lipid transport. These membrane domains are
highly enriched in cholesterol and sphingolipids and have been
shown to be the site of HCV replication (Gao et al., 2004; Shi et al.,
2003). hVAP proteins, residents of lipid raft, interact with NS5A and
NS5B and mediate the formation of the replicase complex (Gao et al.,
2004; Hamamoto et al., 2005). hVAP-A also interacts with anoxysterol-binding protein which is involved in the phosphatidylino-
sitol-regulated homeostasis of cholesterol via regulation of HMG-CoA
reductase. hVAP-A mediates vesicle transport together with the
phosphatidylinositol-transfer protein Sec14 (Wyles and Ridgway,
2003). The required PI(4)P is generated by PIK4Cs identiﬁed in our
siRNA screen to be essential for HCV. PI4KA has been demonstrated by
several other laboratories to be involved in viral replication (Berger et
al., 2009; Tai et al., 2009; Vaillancourt et al., 2009). These results
indicate that HCV depends on an intact protein and lipid transport
pathway. The mRNA proﬁling experiment showed that expression of
the replicon up-regulates sterol as well as phosphatidylinositol
biosynthesis. Inhibition of sterol biosynthesis by statins has been
demonstrated to cause reduction of viral replication (Ikeda and Kato,
2007). siRNAs targeting mRNAs in the sterol biosynthesis pathway
(MVD) or in the trafﬁcking pathway (PIK4C) decreased replication.
Cyclophilin A might contribute to the highly sensitive cholesterol
homeostasis by mediating its transport. HCV depends on cholesterol
and any disturbance in cholesterol level or distribution will decrease
replication.
A third function of Cyclophilin A, regulating transcription, has been
demonstrated recently. Cyclophilin A interacts with Sin3A/Rdp3
HDAC complexes and modulates HDAC-dependent gene silencing in
yeast (Shaw, 2002). The ortholog complex regulates transcription of
theMYC target gene CAD in humans (Pal et al., 2003). CAD, an enzyme
in the pyrimidine de-novo biosynthesis, was one of the strongest hits
in our siRNA screen and it is known that HCV depends on the
pyrimidine de-novo biosynthesis pathway (Stuyver et al., 2003).
In humans, antiviral responses depend on the activation of
transcription, a process that requires the chromatin-remodeling
Table 6
Pathways which are most highly regulated by treatment with NIM811 in naïve Huh7
cells.
Pathway
cluster
Pathway name NIM811 treated vs.
untreated Huh7 cells
Downregulated
Cell–cell
contact
Cell adhesion −12.5
Cell-adhesion mediated signaling −12.3
Cell communication −12.2
Cadherin signaling pathway −8.5
Developmental processes −8.3
Wnt pathway −7.6
Extracellular matrix protein-mediated
signaling
−7.6
Cell structure and motility −6.8
Cell structure −6.4
Other C24_mootha_human −12.2
Signal transduction −11.4
Chromatin packaging and remodeling −8.9
Signaling:homo sapiens:disease:
glioblastoma:responsive genes
−5.6
Coagulation Complement and coagulation cascades −5.4
Blood clotting −4.0
Upregulated
Other Signaling:reference:physiology:apoptosis:
trail mediated apoptosis
3.4
Signaling:homo sapiens:disease:prostate
cancer:trail signaling pathway
Signaling:homo sapiens:disease:melanoma:
trail signaling pathway
3.5
Aminosugar metabolism 3.7
C12_mootha_human 8.5
Protein
trafﬁcking
Protein targeting 3.0
Protein disulﬁde-isomarease reaction 3.2
Protein targeting and localization 3.8
Constitutive exocytosis 4.7
Protein folding 4.8
Protein export 5.7
Exocytosis 8.9
General vesicle transport 11.3
Intracellular protein trafﬁc 61.0
The numbers represent the negative exponent of the p value reported in GSEA. The p
value expresses the probability that a gene set is enriched by chance. The “−” preceding
the number indicates the directionality of regulation; e.g. if it is negative it indicates an
overall down-regulation, if it is missing it indicates an up-regulation.
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transcription and chromatin structure pathways are regulated by
CsA and NIM811 in naïve Huh7 cells—most likely due to inhibiting the
interaction of cyclophilin A with HDACs. In an approach to tag
cyclophilin Awe discovered the protein localizes almost exclusively in
the nucleus of Huh7 cells (data not shown). Proteins involved in
transcription regulation were competed off of cyclophilins by CsA or
NIM811 from the NIM811-covered matrix (Table 3). Cyclophilin A
mRNA depletion had a profound effect on viral replication likely due
to the several functions of this cyclophilin in human cells. Cyclophilin
A inhibition can affect viral replication by either interfering with the
transcription of genes more valuable for the virus than the host cells
such as hVAP, La autoantigen or other cellular factors described to be
necessary for efﬁcient viral replication. Another hypothesis involves
modiﬁcation of virus-induced interferon-mediated gene transcription
which is regulated by HDAC (Cui et al., 2004). Our proﬁling
experiments revealed a more than 5-fold up-regulation of IL-8 levels
upon treatment with CsA or NIM811. This chemokine has been shown
to be up-regulated by recruitment of HDAC1 to its promoter in RSV
infected cells (Jamaluddin et al., 2005).
Cyclophilin B
Cyclophilin B is a membrane bound enzyme of the endoplasmic
reticulum (ER) and Golgi and has also been found to be secreted.
Extracellular cyclophilin B binds to glucosaminoglucans and CD147and stimulates T-lymphocytes (Allain et al., 2002). Proteoglycan core
protein and several proteoglycans have been pulled-down in our
assay together with proteins of the transport machinery (Rab43,
RRBP1, and LEPREL1). Smith et al. (1995) demonstrated that
cyclophilin B transports procollagen from the ER to the Golgi.
Transport of ApoB to the Golgi had been shown to occur in complex
with cyclophilin B and ER chaperones (Zhang and Herscovitz, 2003). It
is therefore possible that cyclophilin B not only binds surface proteins
in the extracellular space, but that it interacts with these proteins and
others such as viral proteins which travel via the secretory pathway as
soon as they are synthesized and enter the ER through the translocon
pore. Cyclophilin B has to be in close proximity of the translocon since
it has been crosslinked to Sec61 (Smith et al., 1995). Protein
trafﬁcking was the most signiﬁcantly affected pathway by treatment
with NIM811 and CsA. It was also up-regulated in Clone A replicon-
containing cells compared to naïve cells indicating that this replicon
depends on the protein trafﬁcking pathway. siRNAs leading to
reduced levels of proteins involved in protein trafﬁcking and
maturation, two processes that depend on each other, reduced viral
replication. Recently, glycosyltransferases have been suggested as
anti-viral targets (Dwek et al., 2002). UDP-glycosyltransferase has
been isolated in a large ER protein complex bound to nascent proteins
which also contained protein disulﬁde isomerase (PDI), cyclophilin B
and other proteins (Meunier et al., 2002). We found proteins involved
in the folding/maturation of proteins of the secretory pathway to be
necessary for viral replication (e.g. LEPRE1, LEPREL1, RPN1). Leprecan,
a prolyl-3-hydroxylase modifying collagens among other proteins,
has been observed in complex with cyclophilin B, FKBP65, Hsp47 (a.k.
a. SERPINH1) and PDI, a prolyl-4-hydroxylase (PDI) (Meunier et al.,
2002). Leprecan was identiﬁed in the compound competition study
(Table 3) and SERPINH1, PDI3 and 4 were identiﬁed in cyclophilin B
pull-down studies (data not shown).
Virus ampliﬁcation and replication has been reported to cause an
Unfolded Protein Response (UPR) which leads to termination of
translation (Tardif et al., 2002). We observed protein biosynthesis
down-regulated by the replicon indicating that the replicon can
induce the same changes as the complete virus.
Cyclophilin B has been demonstrated to be essential for virus-
induced interferon beta expression, suggesting indirect involvement of
cyclophilin B in virus replication (Obata et al., 2005). A direct interaction
of cyclophilin B with NS5B and NS5A has been demonstrated, an
interaction that facilitates RNA binding and replication (Watashi et al.,
2005; Fernandes et al., 2007). Taken together, there seem to be several
ways by which cyclophilin B enables viral replication: by direct
interaction with viral proteins and stimulation of RNA synthesis, by
induction of the UPR, and by inﬂuencing protein trafﬁcking.
Down-regulation of cyclophilin B mRNA did not affect replication
of the Huh-Luc/neo-ET replicon in our experiments but we observed a
signiﬁcant small effect on Clone A cells (data not shown). We are
currently exploring whether this is due to the differences in the viral
RNA or protein sequences or a result of experimental conditions.
Cyclophilin C
Cyclophilin C, similar to cyclophilin B, is located in the ER and Golgi
and can be secreted. Cyclophilin C is induced by interferon (www.
lerner.ccf.org/labs/Williams), and is highly expressed in kidney,
which is thought to be the reason for the kidney toxicity of CsA
(Friedman et al., 1994). This cyclophilin is involved in the innate
immune response via binding to Mac-2BP (LGALS3BP) (Trahey and
Weissman, 1999). Mac-2BP was initially identiﬁed as cyclophilin C-
binding protein (CyC-AP) in mice and the interaction of cyclophilin C
with Mac-2BP is disrupted by CsA (Friedman et al., 1993). CyC-AP
knock out mice are viable, however their survival is decreased upon
endotoxin exposure, which induces IFNγ, TNFα and IL-12 (Trahey and
Weissman, 1999). CyC-AP is thought to be involved in the host
Fig. 4. Several cyclophilin-mediated pathways play a role in maintaining HCV. The scheme depicts the HCV life cycle and the main cellular cyclophilins with the pathways they are
involved in. These pathways have been identiﬁed as important for viral replication in the work presented here.
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virus infection (HIV, HCV) (Grassadonia et al., 2004). The presence of
CyC-AP in body ﬂuids is used as prognostic marker for cancer,
immunodeﬁciencies and for nonresponsiveness of HCV patients to
interferon (Artini et al., 1996; D'Ostilio et al., 1996). Besides binding to
cyclophilin C it also interacts with collagens and ﬁbronectin (Sasaki et
al., 1998) and it stimulates the expression of MHC class I (Grassadonia
et al., 2004). MHC I is one of the most highly regulated pathways in
replicon-containing cells and can be suppressed by treatment with
NIM811 (Table 5). Cell adhesion, cell–cell communication, and
extracellular matrix protein-mediated signaling pathways are
down-regulated by NIM811 and CsA, indicating an involvement of
cyclophilin C. Cyclophilin C is the most highly down-regulated
cyclophilin by the replicon after 48 h and cyclophilin C mRNA
depletion by siRNA treatment does not decrease viral replication.
Several proteoglycans which interact with collagen and syndecan
have been identiﬁed in our pull-down experiments. Based on the
activities of cyclophilin C and cyclophilin B we hypothesize that they
are involved in the trafﬁcking of viral proteins from their site of
translation to the replicase complex.Cyclophilin 40
We will use the term cyclophilin 40 rather than cyclophilin D for
the cytosolic cyclophilin and cyclophilin F to describe the mitochon-
drial cyclophilin to avoid confusion.
Cyclophilin 40 is found in the cytosolic complex transporting
cholesterol together with cyclophilin A and FLBP56. It is also a co-
chaperone in the Hsp90/Hsp70 complex which interacts with a
number of cellular proteins including steroid receptors, kinases such
as Wee, MEK, MAPK, and the transcription factors p53, NF-AT
(Carrello et al., 2004; Taylor et al., 2001). The biological function of
cyclophilin 40 is unknown but it could determine which protein
interacts with the heat shock protein complex since cyclophilin 40
binds to Hsp with its TPR domain leaving the CsA binding domain free
to trigger conformational changes in client proteins by catalyzing cis-
trans isomerization of peptidyl-prolyl bonds (Taylor et al., 2001). A
direct interaction of Hsp90 with the viral NS2/3 protease has been
postulated since geldanamycin, an inhibitor of the ATPase function of
Hsp90, blocked the proteolytic function of this viral protease (Wax-
man et al., 2001). Hsp90 has also been reported to directly interact
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replication (Okamoto et al., 2006). Based on our results, we predict
that cyclophilin 40 competes with other TPR domain containing
proteins for the binding site of heat shock proteins Hsp90 and/or
Hsp70 and controls different functions such as protein degradation
during the UPR that may be caused by stress induced by expression of
the replicon or virus. eIF-2A kinase is a known substrate of Hsp90 and
is involved in the translation attenuation during stress caused by
overload of the ER translocation/modiﬁcation machinery with viral
proteins. dsRNA kinase is another example of Hsp90 client proteins
and it is known to be involved in the antiviral host response
(Balachandran et al., 1998). Thus, there is a large number of Hsp90
client proteins known to be involved in antiviral responses which
could be affected by NIM811 or CsAmediated inhibition of cyclophilin
40. Inhibition of cyclophilin 40 resulted in amoderate decrease of viral
replication (Fig. 1b). In the pulldown experiment several heat shock
proteins were identiﬁed with HSPA8 being signiﬁcantly competed by
NIM811 and CsA but not PSC833. Pathways including Hsp client
proteins are affected by NIM811 and CsA, such as MAP kinases or Fyn
in signaling pathways or protein folding.
Cyclophilin F
Cyclophilin F is a component of the mitochondrial permeability
transition-pore and exhibits anti-apoptotic functions (Schubert and
Grimm, 2004). There is controversial evidence as to whether
cyclosporin treatment provokes pro-apoptotic (Pyrzynska et al.,
2002) or anti-apoptotic activities (Nozynski et al., 2007). NIM811
more strongly upregulates apoptotic pathways thanCsA inour proﬁling
experiments, consistent with their binding afﬁnities to cyclophilin F.
NIM811 binds with equal afﬁnity to cyclophilin F, A and B and it is
therefore surprising that the effect onmitochondria is not stronger than
on protein trafﬁcking, cell–cell contact, or chromatin modeling.
Compound treatment induced a complex regulation of energy
producing pathways in two independent experiments: low concen-
tration of NIM811 up-regulated these pathways whereas at higher
concentration it was inhibitory. In a separate time-course experiment
the same high concentration of NIM811 caused an up-regulation of
energy producing pathways, especially at an earlier time point (12 vs.
48 h). The replicon caused up-regulation at all concentrations and
over time suggesting that the observed drug-mediated regulation is
not an artifact. The number of proteins identiﬁed in the pull-down
experiments that could be associated with cyclophilin F is much
smaller than that of cyclophilin B, A or H. In addition, siRNA mediated
knockdown of cyclophilin F expression did not effect viral replication.
Taken together, the role of cyclophilin F in viral replication is limited.
Cyclophilin G
Cyclophilin G (SR-Cyclophilin, Matrin-Cyclophilin) is a nuclear
matrix protein which interacts with the phosphorylated C-terminal
domain of the largest subunit of RNA polymerase II (POLR2A)
(Bourquin et al., 1997). It contains a large C-terminal serine/arginine
(SR)-rich domain found predominantly in pre-mRNA splicing factors.
Spliceosomal proteins were the second largest group affecting
replication identiﬁed by siRNA. PPWD1 was identiﬁed in our pull-
down assay together with a large number of splicing factors known to
interact with these cyclophilins (AQR, XAB2, LSM2 and 3, CRNKL1,
PRPF8, SART1, SNRPD1, 2 and 3, SNRPE, SNRPF, SNRPG, SNW1). Viral
core protein has been demonstrated to interact with alternative
splicing factor 2 and cause its re-distribution in the cell (A. H. Patel,
14th International Symposium on Hepatitis C virus and related
viruses, Glasgow, UK, 2007). It is clear that the virus exploits the
cellular splicing machinery and the disturbance of splicing therefore
causes replication to cease. The strong effect of cyclophilin inhibiting
compounds can be explained by the presence of several cyclophilinsin the spliceosomal apparatus (cyclophilins G and E, PPWD1, PPPIL1,
PPIL3 and cyclophilin H).
Cyclophilin H
As mentioned above, cyclophilin H is another component of the
spliceosome. The PRPF3 and 4 proteins pulled-down with compounds
are interacting proteins of this cyclophilin.
Like many small RNA viruses, HCV is dependent upon the host cell
and utilizes multiple pathways including protein trafﬁcking, tran-
scription, and splicing for efﬁcient viral replication. The predominant
cyclophilins (A, B, C, H, F and 40) can be linked to these processes,
though it is possible that other cyclophilins are involved as well. Fig. 4
gives an overview of the HCV life cycle and cyclophilins identiﬁed in
our studies with the pathways they are involved in. Although siRNA
screening in combination with drugs successfully identiﬁed chemo-
sensitizer in the past (Whitehurst et al., 2007), the existence of
multiple targets may explain why it was not possible to identify only
one protein by siRNA screening that is involved in synergizing or
antagonizing with NIM811 treatment. Also, it proved extremely
difﬁcult to select NIM811-resistant replicons, further supporting the
possibility of multiple cellular targets. Work will be continued in our
laboratory to shed more insight into the relationship of cyclophilins
and the replication of HCV.
Material and methods
Compounds
CsA, NIM811, cyclophilin analogs (PSC833 and NIM811-NH2),
sanglifehrin A, and sanglifehrin derivatives (compounds 3–7) were
synthesized or isolated at Novartis.
Cell culture
The Con1 subgenomic replicon cell line (Clone A) used for
transcription proﬁling and in siRNA experiments was licensed from
Apath, LLC (St. Louis, MO). The subgenomic replicon containing a
luciferase reporter gene (Huh-Luc/neo-ET) employed in siRNA
experiments and for analysis of compound activities was licensed
from ReBLikon GmbH, Germany. Huh7 cells were maintained in
Dulbecco's Modiﬁed Eagle Medium (DMEM) (Invitrogen) with 10%
Fetal Bovine Serum (Hyclone), 0.1 mM non-essential amino acids
(NEAA) (Invitrogen), and 2 mM L-glutamine (Invitrogen) at 37 °C
with 5% CO2 and split 1:4 to 1:8, twice per week. Medium of the
replicon-containing cells was supplemented with 250 μg/ml G418
(Invitrogen) for Huh-Luc/neo-ET cells and with 500 μg/ml G418 for
Clone A cells.
Replicon assay to measure compound inhibitory effects
The anti-viral activity of compounds was determined using Huh-
Luc/neo-ET cells. Brieﬂy, 5000 replicon cells were seeded in each well
of a 96-well plate and were allowed to attach overnight without G418
selection pressure. On the next day, the culture mediumwas replaced
with medium containing serially diluted compounds in the presence
of 10% FBS and 0.5% DMSO. After 48 h compound treatment, the
luciferase activities in the cells were determined using the BriteLite
reagent (Perkin Elmer) with an LMaxII plate reader (Molecular Probe,
Invitrogen). Four replicates were measured for each data point. IC
50
is
the concentration of compound at which the luciferase activity in the
replicon cells is reduced by 50%.
Cyclophilin binding assay
Initially, the binding of cyclosporin A, NIM811, and other
compounds to cyclophilins was evaluated using a ﬂuorescence
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which was covalently modiﬁed with the ﬂuorophore Atto655 (ATTO-
TECH GmbH) to generate the CsA-Atto655 probe. Brieﬂy, a dose
response curve (10 point, 3-fold dilution) was generated for
compounds, cyclophilin and CsA-Atto655 probe were added subse-
quently and incubated for 30 min at room temperature. All assays
were performed in 96-well plates at a ﬁnal volume of 200 μl run in
triplicate. Plates were read using a BMG PHERAstar (BMG Labtechnol-
ogies) with a FP optic module (excitation: 620–40 nm, emission 1 and
2: 750–50 nm). Milli-anisotropy values were converted to percent
inhibition, plotted vs. log compound concentration, and ﬁtted with
the 4-parameter logistic equation to determine the IC50. IC50 values
were converted to Ki values using a modiﬁed version of the Cheng–
Prusoff equation under a competitive assumption.
Surface plasmon resonance assay
The interaction between unmodiﬁed CsA or NIM811 with various
cyclophilins was studied by immobilizing each individual cyclophilin
protein to a CM5 sensor chip using amine coupling chemistry. Data
obtained in a Biacore T-100 instrument (GE Healthcare) were
analyzed using the BiaEvaluation software (GE Healthcare) to obtain
kon, koff, and KD values.
Transcription proﬁling experiments
Naïve Huh7 cells and Clone A cells were plated at 106 cells per well
in 6-well cell culture plates pre-incubated for 24 h at 37 °C (5% CO2)
and then incubated in fresh medium or medium containing 5 μM CsA
or NIM811 for 12, 24, and 48 h. The experiment was repeated twice to
yield triplicate RNA samples for each condition. In a second
experiment cells were treated with 1 and 5 μM CsA or NIM811 for
48 h to analyze the effects of compound concentration. Total
cytoplasmic RNA was isolated from each sample using the Purescript
RNA Puriﬁcation System Cell and Tissue Kit (Gentra) and RNeasy®
Mini Kit (Qiagen) according to the manufacturer's protocols. Integrity
and purity of RNA was conﬁrmed with the RNA 6000 Nano LabChip
system on Bioanalyzer 2100 (Agilent Technologies; Palo Alto, US). The
double-stranded cDNA synthesis was carried out with 2 to 5 μg of total
RNA (SuperScript double-stranded cDNA synthesis kit; Invitrogen)
according to the manufacturer's instructions. After puriﬁcation
(QIAquick, Qiagen AG), the cDNA was transcribed in vitro in the
presence of biotinylated ribonucleotides (Bioarray High yield T7 DNA
transcription kit, ENZO Life Sciences Inc.). The labeled cRNA was
puriﬁed on an afﬁnity resin (RNeasy, Qiagen AG), quantiﬁed and
fragmented into strands of approximately 50–200 nucleotides in
length. Hybridization to Afﬁmetrix U133 Plus 2 chips was carried out
at 45 °C for approximately 18 h. The arrays were stained on GeneChip
Fluidics Workstation 450 and scanned on GeneArray Scanner 3000
according to manufacturer's technical manual (Affymetrix Inc.). The
scanned image was converted into numerical values of the signal
intensity (Signal) and into categorical expression level measurement
(Absolute Call) using the Affymetrix MAS 5.0 software. (Affymetrix
Inc.). The software scaled the average intensity of each chip to a target
intensity of 150. The MAS 5.0 statistical algorithm parameters used to
attribute the Absolute Calls were set to 0.05 for Alpha 1, 0.065 for
Alpha 2 and 0.015 for Tau. Affymetrix selected QC parameters
“background,” “scaling factor,” 3′/5′ ratios of reference genes (e.g.
GAPDH, beta-actin), were checked for quality control purpose as to
detect arrays that need to be repeated.
The processed arrays were quality checked using BioConductor
packages wrapped in a Perl script. The quality check included the
inspection of the intensity images, the MA plots for each array, the
distribution of raw log2 expression values detected by PM probes and
the distribution of rma normalized log2 expression values in each
array relative to the all arrays in the experiment. The detection ofpathways was performed by Gene Set Enrichment Analysis, GSEA
(Szustakowski et al., 2006).
The complete data set is available at geo@ncbi.nlm.nih.gov, series
GSE15935.
siRNA-mediated down-regulation of mRNA
The siRNAs targeting cyclophilins (purchased from Dharmacon) or
proteins identiﬁed in the chemogenomic approach (designed using
the Biopred algorithm (Huesken et al., 2005)) are listed in tables S1
and4, respectively. Each siRNA was resuspended in siRNA buffer
(Dharmacon) to a stock concentration of 20 μM. The siRNAs were
reverse transfected into Huh-luc/neo-ET cells in a 96-well dish using
Lipofectamine 2000 (Invitrogen) in triplicate. Lipofectamine 2000
(0.25 μl/well) was diluted into 25 μl/well opti-MEM and incubated at
room temperature for 5 min. The siRNA at 150 nM were diluted into
opti-MEM (25 μl/well), and equal amounts of diluted lipofectamine
2000 and diluted siRNAs were mixed, incubated for 30 min at room
temperature, and 50 μl was added to each well in a 96 well dish. Cells
were plated at 8000 cells/100 μl DMEM (10 % FBS, 0.1 % NEAA) over
the siRNA/lipofectamine 2000 mix in each well, giving a ﬁnal siRNA
concentration of 25 nM. Cells were incubated for 72 and 96 h and
assayed for replicon activity by luciferase using the BriteGlow reagent
(Perkin Elmer), or HCV RNA copy number by quantitative real time
PCR (as described inMa et al., 2006) and for cell viability using the Cell
Titer Glow kit (Promega).
siRNA mediated decrease of target mRNA
The effect of siRNAs on their target mRNA level was measured
using the Taqman Gene Expression Assay (Applied Biosystems) per
manufacturer's instructions. Brieﬂy, siRNAs were transfected in Huh7
HCV subgenomic replicon cells in 96 well format as described above.
Total RNA was isolated using the RNeasy96 Kit (Qiagen). cDNA
synthesis was carried out using the High Capacity cDNA reverse
transcription kit (Applied Biosystems). Gene expression analysis was
performed using Taqman probes and primers from Applied Biosys-
tems in 384 well format. Each well contained 5 μl cDNA, 1 μl TaqMan
gene of interest probe, 1 μl β-actin probe and 10 μl Taqman gene
expressionMaster Mix (Applied Biosystems). The reaction was run on
an Applied Biosystems 7900HT Real Time PCR system (Applied
Biosystems).
siRNA screen
The siARRAY Protein Kinase siRNA Library (Dharmacon Technol-
ogies, catalog no. H-003500 of 779 smart pools) and Qiagen 4 siRNAs
targeting 5000 druggable proteins (Human Druggable Genome siRNA
Set X 1.0) were transfected into Huh-luc/neo-ET cells as previously
described (Rines et al., 2008; Hopkins and Groom, 2002). The total
number of siRNA screened was 20,779 of which 20,000 were four
individual Qiagen synthesized siRNAs targeting 5000 druggable genes
and 779 Dharmacon smart pool kinases. The siRNAs were diluted and
stamped out into 384 well tissue culture plates at a concentration of
206 nM diluted in 4 μl Opti-Mem (Invitrogen). Using 0.07 μl of
oligofectamine transfection reagent (Invitrogen) dilutions were
prepared in 4 μl Opti-Mem using the Flex Drop Multi-Dispenser
(Perkin Elmer). The plates were incubated at room temperature for
20–30 min to allow complexes to form. After the incubation, 1500
cells in 25 μl assaymedia were added per well using theMultidrop384
(Thermo Labsystems). Cells were assayed for luciferase activity 72 h
post-transfection using the Bright Glo luciferase assay (Promega) and
the siRNA collections were run in sets of n=2. The screening data was
Z-score transformed to pick siRNAs that scored ≤50% below the
median (≤0.5 or Z-score of −2) or ≥100% (≥2.0 or Z-score of 2)
above the median. Each well was subtracted from the median and
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the absolute value of this number called 1D for one-dimensional
normalization. A value of 0.5 equals two standard deviations below
the median and 2 equals two standard deviations above the median.
For validation experiments each siRNA was resuspended in siRNA
buffer (Dharmacon catalog no. B-002000-UB-015) to a stock concen-
tration of 20 μM. 2.5 μl of each stock solution was diluted in 197.5 μl of
Dharmacon Cell Culture Reagent (DCCR) (Dharmacon, catalog no. B-
004500-100) in a 96 well PCR plate (ABgene) to make a working 10 ×
stamp of 250 μM. Then 0.20 μl of Dharmafect1 (Dharmacon) was
diluted in 10 μl and added to each well of a 96 well tissue culture plate
(Costar). A 10 μl aliquot of each well in the 10× s tamp was added to
the 96 well tissue culture plates containing lipid reagent and
incubated for 20 min at room temperature to allow the complexes
to form. After the incubation, 6000 replicon cells in 80 μl of complete
media was plated on top of the siRNA:lipid reagent complexes using
the Multidrop384 (Thermo Labsystems). In parallel, the same
experiment was set up using 6000 replicon cells, to analyze if the
siRNAs also inhibit luciferase activity in non-replicon dependent cells
(data not shown). Cells were incubated for 72 h at 37 °C and luciferase
activity was measured using the Bright-Glo luciferase assay (Pro-
mega) and cell viability was measured using CellTiter-Glo viability
assay (Promega).
Small molecule afﬁnity chromatography with in-lysate competition
Compound coupling and afﬁnity chromatography was essentially
performed as previously reported (Bantscheff et al., 2007). A NIM811
analog (NIM811-NH2) was synthesized to allow immobilization on
NHS-activated Sepharose 4 beads (Amersham) according to protocols
reported by Smulik et al. (2002). Following coupling, the analog was
treated for 30 min with a tetraﬂuoroacetic acid/dichloromethane/
H2O solution (8/1.5/0.5), washed successively with dichloromethane
and dimethylformamide (all reagents from Sigma) to remove the
protecting t-butyl group and free the protected amine. Huh-7 cells
expressing the Clone A HCV replicon were lysed in a Dounce
homogenizer in ice-cold buffer (50 mM Tris/HCl pH 7.5, 5% glycerol,
1.5 mM MgCl2, 150 mM NaCl, 20 mM NaF, 1 mM Na3VO4, 1 mM DTT,
5 μM calyculin A, 0.8% Igepal-CA630 and a protease inhibitor cocktail
(all reagents from Sigma). Protein concentration was measured after
centrifugation using the Bradford assay. Compounds (CsA, NIM811,
PSC833) were dissolved in dimethyl sulfoxide (DMSO) and added to
50 mg lysate samples at a ﬁnal concentration of 5 μM. The control
sample was treated with DMSO only. After 30 min incubation at 4 °C,
100 μl of NIM811-NH2matrix was added for further 30min incubation
at 4 °C. After centrifugation, beads were transferred into a column
(MoBiTech) and washed. Bound proteins were eluted with NuPAGE
LDS sample buffer (Invitrogen). Eluate samples were then reduced,
alkylated and separated on 4–12% NuPAGE gels (Invitrogen). Gels
were stained with colloidal Coomassie (Sigma).
Mass spectrometry and data analysis
Procedures were essentially performed as previously described
(Bantscheff et al., 2007). In brief, gel lanes were cut into slices across
the full separation range and subjected to in-gel tryptic digestion,
followed by iTRAQ labeling (Applied Biosystems) as described.
Samples derived from the NIM811, CsA, PSC833 and DMSO lanes
were labeledwith iTRAQ reagents 114/115/116/117 respectively and
labeled peptide extracts from the corresponding MW range were
combined prior to MS analysis. Peptide sequencing was performed by
liquid chromatography—tandem mass spectrometry using a self-
packed 75 μm column (C18 Reprosil-Pur ODS-3, 5 μm, Maisch) on a
Waters CapLC coupled to a Q-Tof Ultimamass spectrometer (Waters).
Peptide mass and fragmentation data were used to query an in-house
curated version of the IPI_human database (EBI, http://www.ebi.ac.uk/IPI/) supplemented with sequences of HCV proteins as well as
common non-human contaminant proteins using Mascot (Matrix
Science). Validation of protein identiﬁcations and iTRAQ reporter ion-
based quantiﬁcation was performed using in-house developed
software. Only peptides unique to a set of peptides identifying a
protein were used for relative protein quantiﬁcation. iTRAQ reporter
ion intensities from all spectra matched to a given peptide species in
the total experiment were summed and protein fold changes were
determined from peptide values using a 2-sided linear regression
analysis. Minimum requirements for acceptance of quantiﬁed pro-
teins were at least four quantiﬁable spectra matching to unique
peptides.
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